• Ibotenic Acid: NMDA Receptor Agonist for Neurodegenerative M

  2026-04-13

  Ibotenic acid stands out as a precision NMDA receptor agonist, enabling reproducible animal models of neurodegenerative disorders and sophisticated pain circuit mapping. Its high water solubility, purity, and proven reliability from APExBIO streamline experimental workflows while supporting advanced neuroscience research.

• PML Regulates HIF1AN Ubiquitination to Drive BMSC Osteogenes

  2026-04-13

  This study elucidates how promyelocytic leukemia protein (PML) enhances bone marrow mesenchymal stem cell (BMSC) osteogenic differentiation by promoting HIF1AN ubiquitination and activating the PI3K/AKT pathway. The findings reveal a novel regulatory axis with implications for osteoporosis research and regenerative therapies.

• ABT-737: Unlocking BCL-2 Protein Inhibition in Cancer Models

  2026-04-12

  ABT-737 offers researchers a potent, selective tool for apoptosis induction in diverse cancer cell lines, delivering robust, data-driven performance as a BCL-2 protein inhibitor. This guide details practical workflows, troubleshooting, and applied innovations—empowering translational scientists to harness its full experimental and therapeutic potential.

• Deep Learning Reveals Cardiotoxicity via iPSC-CMs Screening

  2026-04-12

  This study pioneers the integration of deep learning with high-content screening in human induced pluripotent stem cell-derived cardiomyocytes (iPSC-CMs) to detect drug-induced cardiotoxicity. The approach enables scalable, phenotypic assessment of compound libraries, offering valuable insights for early-stage drug discovery and toxicity de-risking.

• ATS-9R: Precision Gene Silencing in Adipocytes for Metabolic

  2026-04-11

  ATS-9R (Adipocyte-targeting sequence-9-arginine) offers unparalleled specificity for gene delivery to white adipose tissue, streamlining workflows in obesity and metabolic disease research. Its prohibitin-mediated targeting, low toxicity, and robust knockdown efficiency position it as a transformative tool for investigators aiming to dissect adipocyte biology and therapeutic gene silencing.

• AMD-070 Hydrochloride: CXCR4 Antagonist for Translational Re

  2026-04-11

  Mavorixafor hydrochloride (AMD-070 hydrochloride) empowers researchers with selective inhibition of the CXCR4/CXCL12 axis for disease modeling and therapeutic discovery. Its robust solubility, safety profile, and compatibility with combination regimens make it an ideal choice for both anti-HIV entry studies and bone marrow migration assays.

• Oxfendazole: Workflow Guidance for Broad Spectrum Anthelmint

  2026-04-10

  Oxfendazole is a high-purity benzimidazole anthelmintic designed for research applications involving energy metabolism disruption in parasitic worms. It provides reliable performance for antiparasitic studies but is not intended for diagnostic or clinical use. Careful attention to solubility, storage, and workflow setup is essential for reproducible results.

• Chlorpromazine HCl: Advanced Mechanisms and Novel Researc...

  2026-04-10

  Discover the intricate neuropharmacology and emerging applications of Chlorpromazine HCl as a dopamine receptor antagonist. This article explores advanced mechanistic insight and highlights innovative directions in psychotic disorder and infection biology research.

• Stiripentol: Noncompetitive LDH Inhibitor for Epilepsy an...

  2026-04-09

  Stiripentol is a validated noncompetitive lactate dehydrogenase (LDH) inhibitor, enabling precise modulation of the astrocyte-neuron lactate shuttle in epilepsy research. Its unique mechanism and robust solubility profile make it a preferred tool for studying metabolic pathways implicated in Dravet syndrome and beyond.

• Chlorpromazine HCl in Translational Research: Mechanistic...

  2026-04-08

  This thought-leadership article explores the multifaceted roles of Chlorpromazine HCl, a phenothiazine antipsychotic and dopamine receptor antagonist, in both neurological and infectious disease research. We examine its mechanistic underpinnings, experimental benchmarks, and translational impact—offering strategic recommendations for researchers leveraging APExBIO’s Chlorpromazine HCl in advanced models of psychotic disorders, dopamine signaling, hypoxia-induced brain injury, and host-directed antibacterial therapies.

• Stiripentol: Unlocking Lactate Epigenetics in Epilepsy an...

  2026-04-08

  Discover how Stiripentol, a noncompetitive LDH inhibitor, enables advanced epilepsy research and unveils a novel link to lactate-driven epigenetic regulation in tumor immunology. Explore its unique mechanism and research applications beyond conventional antiepileptic drug studies.

• Stiripentol and the Next Frontier in LDH Inhibition: Stra...

  2026-04-07

  This thought-leadership article explores the mechanistic and translational impact of Stiripentol—a noncompetitive lactate dehydrogenase (LDH) inhibitor uniquely suited for dissecting the astrocyte-neuron lactate shuttle, metabolic epigenetics, and disease progression. By weaving together insights from recent immunometabolic studies, experimental protocols, and real-world challenges, we establish a roadmap for leveraging Stiripentol in epilepsy and tumor microenvironment research. The discussion goes beyond conventional product pages, guiding researchers toward reproducible, paradigm-shifting discoveries and establishing Stiripentol from APExBIO as a critical tool for next-generation metabolic interrogation.

• Angiotensin 1/2 (2-7): Precision Peptide for Blood Pressu...

  2026-04-07

  Angiotensin 1/2 (2-7) from APExBIO empowers cardiovascular and hypertension researchers with a high-purity, workflow-ready vasoconstrictor peptide fragment. Its outstanding solubility, validated bioactivity, and proven role in renin-angiotensin signaling make it ideal for robust blood pressure regulation and disease modeling studies. Discover protocol enhancements, advanced applications, and troubleshooting strategies that set this peptide apart.

• Rewiring Metabolic Pathways in Epilepsy and Oncology: Str...

  2026-04-06

  This thought-leadership article provides translational researchers with a deep mechanistic understanding and strategic guidance on leveraging Stiripentol—a novel, noncompetitive lactate dehydrogenase (LDH) inhibitor from APExBIO—as a research tool for interrogating the astrocyte-neuron lactate shuttle and metabolic reprogramming in epilepsy and immunometabolism. Incorporating recent findings on lactate's roles in epigenetic regulation and tumor immune evasion, the article explores Stiripentol's experimental and translational potential, sets it apart from typical product-centric content, and connects readers to advanced workflow resources.

• Chlorpromazine HCl: Advanced Insights in Dopamine Antagon...

  2026-04-06

  Explore the multidimensional role of Chlorpromazine HCl as a dopamine receptor antagonist in neuropharmacology and cellular entry research. This deep-dive uncovers novel mechanistic and translational applications, providing researchers with actionable insights beyond standard protocols.

16128 records 1/1076 page Next 12345 下5页 Last page